Cowen Raises Sage Value On New Phase 2 Trial Success
December 07, 2017 at 14:41 PM EST
SAGE Therapeutics Inc (NASDAQ: SAGE) released Thursday positive top-line data from its Phase 2 study of SAGE-217 in major depressive ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|